



To: **The Romanian Financial Supervisory Authority**
Financial Instruments and Investments Sector
The Bucharest Stock Exchange
Regulated Spot Market, Category Standard (Shares)

From: **ZENTIVA S.A.**

CURRENT REPORT

pursuant to art. 122 para. (1) of the Law no. 24/2017 on issuers of financial instruments and market operations and art. 234 para. (1) letter l) of the Financial Supervisory Authority Regulation no. 5/2018 on issuers of financial instruments and market operations

Report date: 14 February 2019

Name of the issuing entity: **ZENTIVA S.A.** (the “**Company**”)

Registered office: 50 Theodor Pallady Blvd.
3rd District, Bucharest
Romania

Phone/Fax number: +4021.304.72.00/ +4021.345.40.04

E-mail/Webpage: www.zentiva.ro

Registration number with the Bucharest Trade Register and sole registration code: J40/363/1991
336206

Share Capital: RON 41,696,115

Number of shares: 416,961,150 shares

Regulated market on which the issued securities are traded: Bucharest Stock Exchange, Main Segment, Category Standard (Shares)

Important events to be reported:

The Company would like to inform its shareholders and investors that on 13 February 2019, the Company has concluded a settlement agreement with ELI LILLY and COMPANY (the “**Settlement**”), in connection with the litigation that is subject of file no. 45087/3/2018 and is pending before the Bucharest Tribunal, 5th Civil Section. The Company has published a current report on 11 January 2019 in connection with the above-mentioned litigation.

The parties agree under the Settlement that ELI LILLY and COMPANY, as claimant, to file a request for withdrawing the injunction in the above-mentioned file. In exchange for ELI LILLY and COMPANY to withdraw the injunction, the Company agreed, inter alia, to recognize ELI LILLY and COMPANY’s intellectual property rights under the national patent no. RO 118374 B1, extended by the



supplemental protection certificate no. c2007059, which confers upon it an exclusive right to use the chemical compound *atomoxetine* in pharmaceutical products used for the treatment of attention deficit hyperactivity disorder, until 27 May 2019.

The Company has also agreed to not manufacture, market, distribute, promote, sell or offer to sell Zentiva products in Romania containing atomoxetine (the “**Products**”) until 27 May 2019, when ELI LILLY and COMPANY’s national patent will expire, to withdraw the selling price of the Products, approved by Order no. 1554/2018 amending and supplementing Annexes no. 1 and 2 of the Order of the Minister of Health no. 1468/2018 and not to have another published price in Romania for the Products until 27 May 2019.

Pursuant to the Settlement, ELI LILLY and COMPANY has the obligation to carry out all the necessary formalities for filing the Settlement with the court for the termination of the proceedings subject to file no. 45087/3/2018, within ten business days of the signing of the Settlement.

Simona Cocos

General Manager